Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

Despite the promising result with FLT3 inhibitors in AML, the emergence of resistance poses a significant challenge, leading to a shorter response duration and inferior survival. This is frequently driven by on-target or parallel prosurvival mutations. The emergence of BCR–ABL1 as a mechanism of pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Alotaibi, Ahmad S., Yilmaz, Musa, Loghavi, Sanam, DiNardo, Courtney, Borthakur, Gautam, Kadia, Tapan M., Thakral, Beenu, Pemmaraju, Naveen, Issa, Ghayas C., Konopleva, Marina, Short, Nicholas J., Patel, Keyur, Tang, Guilin, Ravandi, Farhad, Daver, Naval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606916/
https://www.ncbi.nlm.nih.gov/pubmed/33194747
http://dx.doi.org/10.3389/fonc.2020.588876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606916/
https://www.ncbi.nlm.nih.gov/pubmed/33194747
http://dx.doi.org/10.3389/fonc.2020.588876

Ejemplares similares